MA31169B1 - Preparation solide comprenant de l'alogliptine et de la pioglitazone - Google Patents

Preparation solide comprenant de l'alogliptine et de la pioglitazone

Info

Publication number
MA31169B1
MA31169B1 MA32148A MA32148A MA31169B1 MA 31169 B1 MA31169 B1 MA 31169B1 MA 32148 A MA32148 A MA 32148A MA 32148 A MA32148 A MA 32148A MA 31169 B1 MA31169 B1 MA 31169B1
Authority
MA
Morocco
Prior art keywords
pioglitazone
solid preparation
alogliptin
sugar
excipient
Prior art date
Application number
MA32148A
Other languages
Arabic (ar)
English (en)
Inventor
Junya Nomura
Kenji Nakamura
Kenichiro Kiyoshima
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39240362&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31169(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA31169B1 publication Critical patent/MA31169B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

L'invention porte sur une préparation solide contenant un composé (i), dont la définition est donnée dans la description, et de la pioglitazone, qui est utile comme médicament thérapeutique pour le diabète et similaires et présente des propriétés supérieures de dissolution, de stabilité chimique et de stabilité de dissolution. L'invention porte également sur une préparation solide contenant les première et seconde parties suivantes : (1) la première partie contenant le composé (i) ou un sel de celui-ci et, comme premier excipient, du sucre ou un alcool de sucre ; et (2) une seconde partie contenant de la pioglitazone ou un sel de celle-ci et, comme second excipient, du sucre ou un alcool de sucre.
MA32148A 2007-02-01 2009-08-06 Preparation solide comprenant de l'alogliptine et de la pioglitazone MA31169B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007023594 2007-02-01
PCT/JP2008/051900 WO2008093882A1 (fr) 2007-02-01 2008-01-30 Préparation solide comprenant de l'alogliptine et de la pioglitazone

Publications (1)

Publication Number Publication Date
MA31169B1 true MA31169B1 (fr) 2010-02-01

Family

ID=39240362

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32148A MA31169B1 (fr) 2007-02-01 2009-08-06 Preparation solide comprenant de l'alogliptine et de la pioglitazone

Country Status (39)

Country Link
US (1) US8637079B2 (fr)
EP (1) EP2107905B1 (fr)
JP (1) JP5284968B2 (fr)
KR (1) KR101486091B1 (fr)
CN (1) CN101646420B (fr)
AR (1) AR065097A1 (fr)
AT (1) ATE488227T1 (fr)
AU (1) AU2008211981B2 (fr)
BR (1) BRPI0807453B8 (fr)
CA (1) CA2677201C (fr)
CL (1) CL2008000279A1 (fr)
CR (1) CR10992A (fr)
CY (1) CY1111264T1 (fr)
DE (1) DE602008003522D1 (fr)
DK (1) DK2107905T3 (fr)
DO (1) DOP2009000195A (fr)
EA (1) EA015180B1 (fr)
EC (1) ECSP099608A (fr)
ES (1) ES2354397T3 (fr)
GE (1) GEP20125410B (fr)
HK (1) HK1138188A1 (fr)
HR (1) HRP20110094T8 (fr)
IL (1) IL200108A (fr)
JO (1) JO2650B1 (fr)
MA (1) MA31169B1 (fr)
ME (1) ME01239B (fr)
MX (1) MX2009008100A (fr)
MY (1) MY147596A (fr)
NZ (1) NZ579008A (fr)
PE (1) PE20081663A1 (fr)
PL (1) PL2107905T3 (fr)
PT (1) PT2107905E (fr)
RS (1) RS51592B (fr)
SI (1) SI2107905T1 (fr)
TN (1) TN2009000317A1 (fr)
TW (2) TWI453041B (fr)
UA (1) UA95828C2 (fr)
WO (1) WO2008093882A1 (fr)
ZA (1) ZA200905621B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
CN101437823B (zh) 2006-05-04 2014-12-10 勃林格殷格翰国际有限公司 多晶型
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (fr) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Compositions d'inhibiteurs de la DPP IV
PE20140923A1 (es) * 2007-07-19 2014-08-11 Takeda Pharmaceutical Preparacion solida que comprende alogliptina y clorhidrato de metformina
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
JP5906086B2 (ja) 2008-08-15 2016-04-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Fab関連疾患の治療に用いるためのプリン誘導体
KR20110067096A (ko) 2008-09-10 2011-06-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 및 관련 상태를 치료하기 위한 병용 요법
TW201014850A (en) * 2008-09-25 2010-04-16 Takeda Pharmaceutical Solid pharmaceutical composition
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR20110103968A (ko) 2008-12-23 2011-09-21 베링거 인겔하임 인터내셔날 게엠베하 유기 화합물의 염 형태
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
AR075204A1 (es) 2009-01-29 2011-03-16 Boehringer Ingelheim Int Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
MX2011008416A (es) 2009-02-13 2011-09-08 Boehringer Ingelheim Int Medicaciones antidiabeticas que comprenden un inhibidor de dpp-4 (linagliptina) opcionalmente en combinacion con otros antidiabeticos.
LT2395983T (lt) 2009-02-13 2020-07-10 Boehringer Ingelheim International Gmbh Farmacinė kompozicija, apimanti sglt2 inhibitorių, dpp-iv inhibitorių ir, pasirinktinai, papildomą priešdiabetinį agentą, bei jos panaudojimas
EA034869B1 (ru) * 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
JP2013522279A (ja) 2010-03-18 2013-06-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連状態の治療で用いるgpr119作動薬とddp−iv阻害薬リナグリプチンの組合せ
US20120107398A1 (en) * 2010-05-05 2012-05-03 Boehringer Ingelheim International Gmbh Pharmaceutical compositions
BR112012028136A2 (pt) 2010-05-05 2016-08-09 Boehringer Ingelheim Int terapia de combinaçao
KR20130093012A (ko) 2010-06-24 2013-08-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
CN101912363A (zh) * 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
EP2731947B1 (fr) 2011-07-15 2019-01-16 Boehringer Ingelheim International GmbH Quinazoline dimère substitué, sa préparation et son utilisation dans des compositions pharmaceutiques pour le traitement de la diabète type i et type ii
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び/又はネフローゼ症候群の治療に用いるdpp−4阻害薬としてのキサンチン誘導体
WO2013174767A1 (fr) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
CN103877054B (zh) * 2012-12-21 2016-05-25 北大方正集团有限公司 一种苯甲酸阿格列汀片剂及其制备方法
CN103156819A (zh) * 2013-03-29 2013-06-19 山东罗欣药业股份有限公司 苯甲酸阿格列汀组合物片剂及其制备方法
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
WO2016104643A1 (fr) * 2014-12-25 2016-06-30 田辺三菱製薬株式会社 Préparation solide destinée au traitement du diabète
EP3310357A1 (fr) * 2015-06-17 2018-04-25 H e x a l Aktiengesellschaft Formulation d'alogliptine
JP2018518521A (ja) * 2015-06-26 2018-07-12 コリア ユナイテッド ファーマ. インコーポレーテッド モサプリドとラベプラゾールの複合製剤
CN105030719B (zh) * 2015-08-20 2018-07-20 杭州成邦医药科技有限公司 一种含有阿格列汀和吡格列酮的组合物
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
KR102485766B1 (ko) 2019-12-11 2023-01-09 한국유나이티드제약 주식회사 생체이용률이 향상된 피오글리타존 함유 약학조성물
CN113925838B (zh) * 2021-11-11 2022-11-11 乐普制药科技有限公司 一种依帕司他与西格列汀或其可药用盐的复方缓释片及其制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
AU8941491A (en) 1990-11-27 1992-06-25 Byk Gulden Lomberg Chemische Fabrik Gmbh Retarded-action urapidil formulation
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
JP2931811B2 (ja) 1997-06-03 1999-08-09 ユニコロイド株式会社 徐放性カプセル
US6030641A (en) 1997-06-03 2000-02-29 Uni Colloid Kabushiki Kaisha Sustained release capsule and method for preparing the same
WO1998056359A2 (fr) 1997-06-13 1998-12-17 Roland Bodmeier Compositions retardant la liberation de principes actifs
DE19725911A1 (de) 1997-06-13 1998-12-17 Roland Prof Dr Bodmeier Zusammensetzungen, die die Wirkstofffreisetzung verzögern
JP2000154137A (ja) 1998-09-18 2000-06-06 Takeda Chem Ind Ltd 徐放性経口製剤
WO2000016776A1 (fr) 1998-09-18 2000-03-30 Takeda Chemical Industries, Ltd. Preparations a administrer par voie buccale a liberation lente
PT1133312E (pt) 1999-06-21 2007-11-30 Lilly Co Eli Uso sinergístico de tiazolidinodionas com péptido 1 semelhante ao glucagon e os seus agonistas para tratar diabetes não insulino-dependente
AR030920A1 (es) 1999-11-16 2003-09-03 Smithkline Beecham Plc Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
PT1741447E (pt) 2000-01-21 2013-12-11 Novartis Ag Combinações que compreendem o inibidor da dipeptidilpeptidase-iv
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US7078397B2 (en) 2000-06-19 2006-07-18 Smithkline Beecham Corporation Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
US6573287B2 (en) 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US8329217B2 (en) * 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
WO2004006921A1 (fr) 2002-07-11 2004-01-22 Takeda Pharmaceutical Company Limited Procede de production d'une preparation recouverte
IN192749B (fr) 2002-11-15 2004-05-15 Ranbaxy Lab Ltd
CA2514539C (fr) 2003-01-29 2012-03-06 Takeda Pharmaceutical Company Limited Procede pour realiser une preparation enrobee
JP4567340B2 (ja) * 2003-01-29 2010-10-20 武田薬品工業株式会社 被覆製剤の製造方法
CN1874774B (zh) 2003-10-31 2011-04-13 武田药品工业株式会社 包含胰岛素致敏剂、胰岛素促分泌素和聚氧乙烯脱水山梨醇脂肪酸酯的固体制剂
JP4361461B2 (ja) 2003-10-31 2009-11-11 武田薬品工業株式会社 固形製剤
ES2940341T3 (es) 2004-01-20 2023-05-05 Novartis Ag Formulación y proceso de compresión directa
BRPI0418639B8 (pt) 2004-03-15 2021-05-25 Takeda Pharmaceutical compostos inibidores de dipeptidil peptidase, assim como composição farmacêutica contendo os mesmos
EP1807066A1 (fr) 2004-10-25 2007-07-18 Novartis AG Combinaison d'inhibiteur de la dpp-iv, d'antidiabetique ppar et de metformine
GT200600218A (es) 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
HRP20140091T4 (hr) 2005-09-14 2021-12-24 Takeda Pharmaceutical Company Limited Davanje inhibitora dipeptidil peptidaze
TW200745079A (en) 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
BRPI0620718A2 (pt) 2005-10-28 2011-11-22 Takeda Pharmaceutical agente para a proteção do páncreas, e, uso de uma droga para a redução de glicose
TWI384985B (zh) 2005-12-22 2013-02-11 Takeda Pharmaceutical 固體製劑

Also Published As

Publication number Publication date
DK2107905T3 (da) 2011-01-31
JP2010517937A (ja) 2010-05-27
CN101646420B (zh) 2012-11-07
EP2107905B1 (fr) 2010-11-17
ME01239B (me) 2013-06-20
US20100092551A1 (en) 2010-04-15
CN101646420A (zh) 2010-02-10
CA2677201A1 (fr) 2008-08-07
PL2107905T3 (pl) 2011-04-29
GEP20125410B (en) 2012-02-27
JO2650B1 (en) 2012-06-17
BRPI0807453A2 (pt) 2014-05-20
IL200108A0 (en) 2010-04-15
ES2354397T3 (es) 2011-03-14
RS51592B (en) 2011-08-31
WO2008093882A1 (fr) 2008-08-07
PE20081663A1 (es) 2008-12-25
AR065097A1 (es) 2009-05-13
JP5284968B2 (ja) 2013-09-11
CA2677201C (fr) 2015-11-17
ATE488227T1 (de) 2010-12-15
CR10992A (es) 2009-09-16
MY147596A (en) 2012-12-31
EP2107905A1 (fr) 2009-10-14
EA200970726A1 (ru) 2010-02-26
HRP20110094T8 (en) 2011-07-31
IL200108A (en) 2012-02-29
KR101486091B1 (ko) 2015-01-23
HK1138188A1 (en) 2010-08-20
TN2009000317A1 (en) 2010-12-31
AU2008211981B2 (en) 2012-09-20
PT2107905E (pt) 2010-12-17
SI2107905T1 (sl) 2011-03-31
US8637079B2 (en) 2014-01-28
BRPI0807453B8 (pt) 2021-05-25
NZ579008A (en) 2012-02-24
TWI453041B (zh) 2014-09-21
KR20090109115A (ko) 2009-10-19
ZA200905621B (en) 2010-10-27
BRPI0807453B1 (pt) 2021-01-05
DOP2009000195A (es) 2009-08-31
TW200836775A (en) 2008-09-16
AU2008211981A1 (en) 2008-08-07
CL2008000279A1 (es) 2008-08-18
ECSP099608A (es) 2009-09-29
EA015180B1 (ru) 2011-06-30
TW201350143A (zh) 2013-12-16
MX2009008100A (es) 2009-08-07
HRP20110094T1 (hr) 2011-03-31
UA95828C2 (ru) 2011-09-12
DE602008003522D1 (de) 2010-12-30
CY1111264T1 (el) 2015-08-05

Similar Documents

Publication Publication Date Title
MA31169B1 (fr) Preparation solide comprenant de l'alogliptine et de la pioglitazone
Nagel et al. Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL
MA30890B1 (fr) Compose indole
Lim et al. Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction
Saxena et al. Drug/drug interaction of common NSAIDs with antiplatelet effect of aspirin in human platelets
Rudic et al. COX-2–derived prostacyclin modulates vascular remodeling
MA27058A1 (fr) Cristaux comprenant un sel d'acide malique de n-[2-(diethylamino) ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indole-3-ylidene) methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide, procedes pour leur preparation et compositions les contenant
WO2001081310A8 (fr) 1-aroyle-piperidinyle benzamidines
BR0007820A (pt) Formulações agonistas de exendina e métodos deadministração das mesmas
MA31592B1 (fr) Preparation solide comprenant l'alogliptine et le chlorhydrate de metformine
MA29550B1 (fr) Derives de n- (pyridine-2-yl) - sulfonamide
MA33056B1 (fr) Composition pharmaceutique solide comprenant de l'amlodipine et du losartan et son procede de fabrication
HUP0401998A2 (hu) PDE9 inhibitorok alkalmazása olyan gyógyszer előállítására, amellyel inzulin-rezisztencia szindróma és 2-es típusú diabétesz kezelhető
MA32027B1 (fr) Preparation de capsules
WO2004112701A3 (fr) Derives de cyclohexylglycine servant d'inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete
MA28673B1 (fr) Derives de pyrazole, compositions contenant lesdits composes et methodes d'utilisation
MA32171B1 (fr) Compose heterocyclique
MA29791B1 (fr) Composes therapeutiques.
MA29543B1 (fr) Procedes pour traiter un cancer pharmacoresistant
WO2004069162A3 (fr) Derives d'acide 3-amino-4-phenylbutanoique utilises comme inhibiteurs de dipeptidyle peptidase pour le traitement ou la prevention du diabete
WO2004064778A3 (fr) Derives d'acide 3-amino-4-phenylbutanoique utilises comme inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete
WO2004103276A3 (fr) Derives d'acide 3-amino-4-phenylbutanoique en tant qu'inhibiteurs de dipeptidyl peptidase dans le cadre du traitement ou de la prevention du diabete
CN101277687A (zh) 以2-氨基-1,3-丙二醇衍生物作为有效成分的肝脏疾病治疗剂及肝脏疾病治疗方法
Azam et al. Parasitic diarrheal disease: drug development and targets
DK1888074T3 (da) Middel til forebyggelsen og behandling af leversygdomme indeholdende pyrazolopyrimidinderivat